MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
2.490
-0.260
-9.45%
Opening 14:13 10/13 EDT
OPEN
2.730
PREV CLOSE
2.750
HIGH
2.730
LOW
2.475
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
4.330
52 WEEK LOW
1.660
MARKET CAP
382.41M
P/E (TTM)
-3.3445
1D
5D
1M
3M
1Y
5Y
1D
Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift
Seeking Alpha · 1d ago
Weekly Report: what happened at EDIT last week (1005-1009)?
Weekly Report · 1d ago
Wells Fargo Upgrades Editas Medicine to Overweight from Equal-Weight
NASDAQ · 4d ago
Editas upgraded at Wells Fargo as Australia approves gene editing trial
Seeking Alpha · 5d ago
Editas Medicine Price Target Raised to $6.00/Share From $4.00 by Wells Fargo
Dow Jones · 5d ago
Editas Medicine Raised to Overweight From Equal-Weight by Wells Fargo
Dow Jones · 5d ago
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Benzinga · 5d ago
Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light
TipRanks · 5d ago
More
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.